Atrial Fibrillation Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes) with at least one episode in the past 12 months — though people already taking heart rhythm medications may not need to meet this requirement
• People who have had at least one episode of this irregular heartbeat confirmed by a heart tracing test such as an ECG, Holter monitor, or similar recording device
• People who are able to understand and sign an informed consent form

Who may not be able to join:

• People whose atrial fibrillation is persistent or permanent (meaning it does not stop on its own or has been present long-term)
• People who have previously had a catheter-based or surgical procedure to treat atrial fibrillation or certain other heart rhythm conditions
• People who have been diagnosed with certain other heart rhythm conditions (such as AVNRT, AVRT, atrial tachycardia, or atrial flutter) before joining the trial
• People who have previously had a procedure or surgery involving the left upper chamber of the heart
• People who have a history of narrowing or a stent in the pulmonary veins (blood vessels connecting the lungs to the heart)
• People who already have paralysis of one side of the diaphragm (the main breathing muscle)
• People who have a blood clot currently present inside the heart
• People for whom blood-thinning medication is not medically appropriate
• People currently taking immune-suppressing medications, unless a treating doctor determines it is safe to stop those medications for three months before and three months after the procedure (confirm with trial site)
• People whose atrial fibrillation is caused by a treatable condition, such as an uncontrolled thyroid problem or recent heart surgery within the past six months
• People whose heart pumping function is significantly reduced (left ventricular ejection fraction below 35%)
• People with the most severe level of heart failure symptoms (NYHA Class 4)
• People diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick)
• People with moderate or severe disease of the mitral or aortic heart valves
• People who have a mechanical replacement valve in the mitral position
• People with a known allergic or adverse reaction to the medication adenosine
• People with advanced chronic kidney disease (Stage 4 or higher)
• People with significant structural heart abnormalities present from birth, such as holes between the upper heart chambers or abnormal pulmonary veins — though people with a small natural opening called a patent foramen ovale are not excluded
• People who are pregnant
• People who have had a stroke or mini-stroke (transient ischemic attack) in the six months before consenting to the trial
• People who have had a blood clot-related event in the six months before joining
• People who are currently enrolled in, or expected to join, another clinical trial of a drug, device, or biological treatment that could affect this trial's results
• People with primary pulmonary hypertension (high blood pressure in the lungs not caused by another condition)
• People with rheumatic heart disease
• People with conditions affecting platelet levels or blood clotting
• People with an active infection anywhere in the body
• People whose life expectancy is less than 12 months
• People who are unwilling or unable to follow the study procedures and attend follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.